Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI plus bevacizumab (FTD-TPI plus bev) combination therapy.

被引：0
|
作者：
Nusrat, Maliha
Zhao, Ruizhi
Khan, Nadeem
Wang, Yuexi
Pierre-Victor, Dudith
Tepsick, Jon G.
Sharath, R.
Cann, Christopher G.
Salimi, Tehseen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] ConcertAI LLC, Cambridge, MA USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 45 条
  • [1] Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI plus bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC).
    Zhao, Ruizhi
    Khan, Nadeem
    Wang, Yuexi
    Pierre-Victor, Dudith
    Tepsick, Jon G.
    Sharath, R.
    Cann, Christopher G.
    Salimi, Tehseen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [2] Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.
    Yoshino, Takayuki
    Taieb, Julien
    Andre, Thierry
    Kuboki, Yasutoshi
    Pfeiffer, Per
    Kumar, Amit
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.
    Hubbard, Joleen M.
    Lee, Lulu K.
    Grisolano, Jay L.
    Perkowski, Kacper
    Salimi, Tehseen
    Kazerooni, Reza
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 34 - 34
  • [5] Efficacy and safety of trifluridine/tipiracil and bevacizumab (FTD/TPI plus BEV) in patients with metastatic colorectal cancer (mCRC) in real-world practice.
    Lago, Nieves Martinez
    Reboredo, Margarita
    Gonzalez Gomez, Borja
    de Frutos Gonzalez, Belen
    Riesco Martinez, Maria Carmen
    Antonilli, Paula Carla
    Lopez Alfonso, Ana
    Gallardo Martin, Elena
    Fernandez Montes, Ana Fernandez
    Cabezon-Gutierrez, Luis
    Castineira, Antia Cousillas
    Ferreiro, Reyes
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 204 - 204
  • [6] Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.
    Lago, Nieves Martinez
    Gonzalez, Borja
    Martin, Elena Gallardo
    Montes, Ana Fernandez
    Castineira, Antia Cousillas
    Suarez, Begona Grana
    Maseda, Alberto Carral
    Augusto, Maria Luz Pellon
    Villarroel, Paula Gonzalez
    Gomez, Juan De La Camara
    Fernandez, Mercedes Salgado
    Lopez, Margarita Reboredo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 51 - 51
  • [7] Frequency and management of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
    Lago, N. Martinez
    Rendo, C. Reboredo
    Chucla, T. Calleja
    Salvador, M. Mateos
    Fernandez, F. Busto
    Gomez, J. de la Camara
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S100 - S101
  • [8] Trifluridine-tipiracil (FTD/TPI) plus bevacizumab (BV) in patients (pts) with pretreated metastatic colorectal cancer (mCRC): A real-life Italian multicenter experience
    Trovato, G.
    Carullo, M.
    Zoratto, F.
    Tamberi, S.
    Bergamo, F.
    Basso, M.
    Calegari, M. A.
    Puccini, A.
    Pastorino, A.
    Schirripa, M.
    Lucchetti, J.
    Arrivi, G.
    Morelli, C.
    Cerma, K.
    Troiani, T.
    Morano, F.
    Cremolini, C.
    Martinelli, E.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S45 - S45
  • [9] Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).
    Patel, Anuj K.
    Barghout, Victoria
    Yenikomshian, Mihran Ara
    Germain, Guillaume
    Jacques, Philippe
    Laliberte, Francois
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [10] Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
    Yamazaki, K.
    Satake, H.
    Takashima, A.
    Mizusawa, J.
    Kataoka, T.
    Fukuda, H.
    Ishizuka, Y.
    Suwa, Y.
    Numata, K.
    Shibata, N.
    Asayama, M.
    Yokota, M.
    Tsushima, T.
    Ohta, T.
    Yamaguchi, T.
    Hamaguchi, T.
    Kanemitsu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S738 - S738
12345